Geron Corporation GERN gained 18.4% to $3.61 following announcement of the NEJM articles mentioning transformative potential of imetelstat in hematologic myeloid malignancies. Share volume was 8.7 million, routing an all-day average of 2.4 million
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
